GE HealthCare has agreed to acquire SOFIE Biosciences for $945 million in cash, expanding its position in the fast-growing U.S. radiopharmaceutical market. The deal, announced on October 5, 2026, gives GE HealthCare a network of specialized manufacturing sites across the United States and U.S. rights to an experimental PET imaging agent being studied for use across multiple types of cancer.
The transaction has been announced but has not yet been completed. GE HealthCare expects it to close in the first half of 2027, subject to regulatory approvals and other customary closing conditions.
What Is GE HealthCare Buying for $945 Million?
SOFIE Biosciences is a U.S.-based company specializing in radiopharmaceuticals used with PET imaging. These are radioactive drugs given to patients before a PET scan. They allow doctors to see biological activity inside the body and can help detect and understand diseases, including cancer.
The unusual part of this business is that some of these products cannot simply be manufactured in one large factory and shipped across the country. Fluorine-18, or F18, which is used in many PET radiopharmaceuticals, has a half-life of about 110 minutes. In simple terms, its radioactivity declines very quickly. That makes proximity to hospitals and imaging centers extremely important because the product must be manufactured, transported and used within a relatively short period.
This is where SOFIE becomes strategically valuable. The company operates 15 manufacturing sites across the United States with 21 cyclotrons, machines used to produce the radioactive isotopes needed for PET drugs. It also operates a development and manufacturing site focused on theranostics, an emerging area that combines diagnosis with targeted treatment.
GE HealthCare is therefore not simply buying another healthcare product. It is buying a U.S. manufacturing and distribution network that can help it deliver time-sensitive radiopharmaceuticals closer to patients.
Why Does GE HealthCare Want SOFIE?
The acquisition is designed to give GE HealthCare a stronger position across the entire radiopharmaceutical supply chain.
GE HealthCare already sells medical imaging equipment and pharmaceutical diagnostic products. Its Pharmaceutical Diagnostics business provides imaging agents used in millions of procedures around the world. SOFIE adds something different: a physical U.S. production network close to the hospitals and imaging centers that actually use PET radiopharmaceuticals. GE HealthCare describes this as establishing a “final mile” footprint in the United States.
The idea is relatively simple. Developing a promising PET imaging drug is only part of the business. A company also needs the ability to manufacture that drug reliably and deliver it quickly enough for hospitals to use it. Owning SOFIE would give GE HealthCare more direct access to that infrastructure.
The acquisition also fits into a broader strategy of providing technology across more stages of medical imaging and precision medicine — from the equipment used to produce radioactive isotopes to imaging systems, software and the pharmaceutical products used during scans.
FAPI-74 Could Be One of the Most Important Assets in the Deal
SOFIE brings another potentially valuable asset: U.S. rights to FAPI-74, an experimental F18 PET imaging agent currently in Phase III development. GE HealthCare already holds rights to FAPI-74 outside the United States through an agreement with SOFIE dating back to 2023. Acquiring the company would bring the U.S. rights under GE HealthCare as well.
FAPI-74 targets fibroblast activation protein, or FAP, which is found at high levels in the environment surrounding many types of tumors. That has made FAP-targeted imaging an important area of research because a single imaging approach could potentially have applications across several types of cancer rather than being limited to one specific disease. GE HealthCare describes FAPI-74 as having potential for pan-cancer imaging, although investors should keep an important distinction in mind: the product remains in clinical development.
Phase III development is an advanced stage, but it does not guarantee regulatory approval or commercial success. Still, acquiring the U.S. rights gives GE HealthCare greater exposure to the potential upside if FAPI-74 ultimately reaches the market.
Why Radiopharmaceuticals Are Becoming More Important
The acquisition comes as pharmaceutical companies and medical technology businesses increase their investment in radiopharmaceuticals.
Traditional medical imaging largely helps doctors see where a disease is located. Newer radiopharmaceutical approaches can provide information about biological processes occurring inside tumors and other tissues.
The same basic targeting concept can also be used in theranostics. Instead of only identifying a target inside the body, a related radioactive compound can potentially deliver radiation directly to diseased cells. That creates a connection between diagnosis and targeted treatment.
The development pipeline is expanding accordingly. GE HealthCare said there are approximately 20 PET radiotracers and more than 30 radiotherapeutics under development across the industry.
That growth creates demand not only for new drugs but also for the specialized manufacturing and distribution infrastructure required to deliver them. SOFIE gives GE HealthCare exposure to both sides of that expansion.
What Could SOFIE Add to GE HealthCare's Business?
GE HealthCare generated approximately $20.6 billion in revenue in 2025, making the $945 million acquisition meaningful but manageable relative to the size of the company.
Management expects SOFIE's business to grow at a low-double-digit rate after becoming part of GE HealthCare. The company also expects the acquisition to improve revenue growth, adjusted operating profitability and adjusted earnings per share during the first full year of ownership.
Those are management expectations rather than guaranteed results.
The more important long-term question is whether GE HealthCare can use SOFIE's manufacturing network to expand its own radiopharmaceutical portfolio while continuing to manufacture products for other companies. GE HealthCare says SOFIE will continue serving its existing customers after the transaction closes, including other radiopharmaceutical providers.
That means SOFIE could provide GE HealthCare with both strategic infrastructure for its own products and manufacturing revenue from outside customers.
What Does the Deal Mean for GE HealthCare Investors?
For GE HealthCare investors, the acquisition is primarily a bet on the continued growth of precision medicine, PET imaging and radiopharmaceuticals.
The immediate financial impact is only part of the story. GE HealthCare is strengthening its ability to participate in several stages of the market: producing imaging agents, manufacturing them close to patients, supplying imaging equipment and developing technologies connected with targeted diagnosis and treatment. That could become increasingly valuable if more radiopharmaceutical products receive regulatory approval and adoption grows.
But there are also risks. GE HealthCare is paying $945 million in cash, and part of the strategic value of the acquisition depends on future growth in a market where many products remain in development. FAPI-74 itself still has to successfully complete development and clear the necessary regulatory hurdles.
There is also execution risk. Owning manufacturing infrastructure does not automatically guarantee that new radiopharmaceutical products will become commercially successful.
Investors therefore have two separate questions to consider: whether the radiopharmaceutical market continues to expand as expected, and whether GE HealthCare can turn SOFIE's network and pipeline assets into meaningful long-term growth.
The Deal Is Part of a Broader GE HealthCare Expansion
The SOFIE acquisition also follows another major transaction by GE HealthCare. In March 2026, the company completed its $2.3 billion acquisition of medical imaging software provider Intelerad, strengthening its cloud, software and enterprise imaging capabilities.
The two acquisitions target different parts of healthcare technology, but together they illustrate how GE HealthCare is expanding beyond traditional medical equipment. Intelerad strengthened the digital and software side of medical imaging. SOFIE would strengthen the pharmaceutical manufacturing and distribution side.
That creates a broader business spanning imaging hardware, software, pharmaceutical diagnostics and increasingly specialized precision-medicine infrastructure.
What Happens Next?
The most immediate milestone is regulatory approval and completion of the transaction. GE HealthCare expects the acquisition to close in the first half of 2027, after which SOFIE would become part of its Pharmaceutical Diagnostics segment.
After closing, investors will be able to watch whether SOFIE delivers the low-double-digit growth GE HealthCare expects and whether the acquisition begins contributing to earnings as planned.
FAPI-74 will be another important development to follow. Progress through Phase III testing and any eventual regulatory decisions could significantly affect the value of the U.S. rights GE HealthCare is acquiring.
The larger story, however, goes beyond one experimental drug. GE HealthCare is spending $945 million to secure a physical U.S. network capable of manufacturing and rapidly distributing a new generation of PET radiopharmaceuticals. If precision imaging and targeted radiopharmaceutical therapies continue to expand, that network could become an increasingly important part of the company's healthcare platform.
This article is for informational purposes only and does not constitute investment advice. Always do your own research before making investment decisions.
